Cardiomyopathies

The cardiomyopathy landscape has been redrawn in less than five years. Sessions cover hypertrophic cardiomyopathy with myosin inhibitors (mavacamten, aficamten), dilated cardiomyopathy genetics and management, restrictive cardiomyopathies including ATTR amyloidosis and its TTR-stabilisers and silencers, arrhythmogenic right-ventricular cardiomyopathy, peripartum and stress-induced cardiomyopathies, and rare phenotypes including Fabry and sarcoid. Discussion includes family screening, advanced imaging for tissue characterisation, and the bridge from genotype to targeted therapy.